ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1633

Epidemiology of Musculoskeletal Manifestations in Paediatric Inflammatory Bowel Disease: A Systematic Review

Aaisham Ali1, Melanie Schmidt2, David Piskin2, Eileen Crowley3 and Roberta Berard4, 1Schulich School of Medicine & Dentistry, London, ON, Canada, 2Lawson Health Research Institute, London, ON, Canada, 3Department of Paediatrics, Division of Paediatric Gastroenterology, Children's Hospital, London Health Sciences Centre, London, ON, Canada, 4London Health Sciences Centre, London, ON, Canada

Meeting: ACR Convergence 2021

Keywords: Diagnostic criteria, Disease Activity, Epidemiology, Musculoskeletal Examination, Pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Paediatric inflammatory bowel disease (p-IBD) is a chronic and relapsing gastrointestinal disorder of childhood with associated long-term morbidity. Several extraintestinal manifestations (EIMs) are described, the most common being joint pain and/or inflammation. In 1986, Passo et al. were the first to describe the association of arthritis in p-IBD patients. In this retrospective study, arthritis was described in 9% of children with ulcerative colitis (UC) and in 15.5% of children with Crohn’s disease (CD). Arthralgia was more common than arthritis, occurring in 32% of patients with UC and 22% with CD. Data on the epidemiology, patient and disease factors associated with the development of, treatments required for, and outcomes of p-IBD associated musculoskeletal (MSK) disease is lacking. Our study aims to summarize the literature on the epidemiology of MSK EIMs in p-IBD in the era of biologics.

Methods: A systematic review of the literature was performed. PubMed, Embase, Cochrane Library, Web of Science Core Collection, and CINAHL databases were searched with relevant keywords. English studies published from January 1, 2000 to December 21, 2020 were included. In total, 3,893 papers were identified, and screening was performed by two independent reviewers (AA, MS; Figure 1). Conflicts were resolved by a third reviewer (EC or RB). Characteristics of the study such as research design, setting, and sample size, as well as phenotypic characteristics of the population were recorded. The primary outcomes of interest were MSK symptoms at presentation and course, method of diagnosis and definitions used for MSK EIMs. Risk of bias assessment was performed using the JBI Prevalence Study Critical Appraisal Tool.

Results: Thirteen studies were included for full review, which were primarily single-centre observational studies with retrospective or cross-sectional design. The method of diagnosis for MSK EIMs varied greatly across the studies, with only 4 studies stating the involvement of a rheumatologist in the diagnosis. The definitions used also varied, with MSK-related features such as peripheral arthritis, axial arthritis, enthesopathy, myalgia, and arthralgia included. Only 6 studies focused on MSK EIMs as their primary outcome, while the remainder reported on all p-IBD associated EIMs. There was a wide range in the prevalence of MSK EIMs from 3.7-34.8% (Figure 2a, 2b). Four studies reported on the therapeutic response of MSK EIMs to pharmacotherapy, and only 3 of those reported on biologic use. Risk of bias demonstrated heterogeneity in the quality of included studies.

Conclusion: This is the first systematic review of the literature for MSK EIMs in p-IBD. Analysis was limited due to variability in study design and data-reporting methods. Included studies reported prevalence of MSK EIMs, but the ascertainment of MSK EIMs, both method and definition varied with a clear lack in standardization. Our study demonstrates the need for research to capture the presentation, diagnosis, management, and morbidity associated with MSK EIMs in p-IBD.

PRISMA flowchart for study inclusion

MSK EIM reported prevalence rates


Disclosures: A. Ali, None; M. Schmidt, None; D. Piskin, None; E. Crowley, AbbVie, 5, 6, Alimentiv, 2; R. Berard, Sandoz, 2, SOBI, 2, Roche, 2.

To cite this abstract in AMA style:

Ali A, Schmidt M, Piskin D, Crowley E, Berard R. Epidemiology of Musculoskeletal Manifestations in Paediatric Inflammatory Bowel Disease: A Systematic Review [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/epidemiology-of-musculoskeletal-manifestations-in-paediatric-inflammatory-bowel-disease-a-systematic-review/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-of-musculoskeletal-manifestations-in-paediatric-inflammatory-bowel-disease-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology